197 related articles for article (PubMed ID: 17465867)
1. Determinants of liver damage associated with intravenous methylprednisolone pulse therapy in Graves' ophthalmopathy.
Le Moli R; Baldeschi L; Saeed P; Regensburg N; Mourits MP; Wiersinga WM
Thyroid; 2007 Apr; 17(4):357-62. PubMed ID: 17465867
[TBL] [Abstract][Full Text] [Related]
2. Age and Dose Are Major Risk Factors for Liver Damage Associated with Intravenous Glucocorticoid Pulse Therapy for Graves' Orbitopathy.
Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Vitti P; Marcocci C; Brunetto M; Marinò M
Thyroid; 2015 Jul; 25(7):846-50. PubMed ID: 26090805
[TBL] [Abstract][Full Text] [Related]
3. Acute liver damage following intravenous glucocorticoid treatment for Graves' ophthalmopathy.
Moleti M; Giuffrida G; Sturniolo G; Squadrito G; Campennì A; Morelli S; Puxeddu E; Sisti E; Trimarchi F; Vermiglio F; Marinò M
Endocrine; 2016 Oct; 54(1):259-268. PubMed ID: 27003434
[TBL] [Abstract][Full Text] [Related]
4. [Steroid therapy for Graves' ophthalmopathy].
Hiromatsu Y
Nihon Rinsho; 2006 Dec; 64(12):2279-85. PubMed ID: 17154092
[TBL] [Abstract][Full Text] [Related]
5. Blood Pressure Profile and N-Terminal-proBNP Dynamics in Response to Intravenous Methylprednisolone Pulse Therapy of Severe Graves' Orbitopathy.
Miskiewicz P; Milczarek-Banach J; Bednarczuk T; Opolski G; Glowczynska R
Int J Mol Sci; 2018 Sep; 19(10):. PubMed ID: 30261581
[TBL] [Abstract][Full Text] [Related]
6. High dose intravenous methylprednisolone pulse therapy causes transient increase of serum calcium and phosphate levels.
Rymuza J; Popow M; Bednarczuk T; Miśkiewicz P
Pol Merkur Lekarski; 2019 Sep; 47(279):91-94. PubMed ID: 31557136
[TBL] [Abstract][Full Text] [Related]
7. Methylprednisolone and hepatotoxicity in Graves' ophthalmopathy.
Wichary H; Gasińska T
Thyroid; 2012 Jan; 22(1):64-9. PubMed ID: 22029719
[TBL] [Abstract][Full Text] [Related]
8. Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves' ophthalmopathy.
Aktaran S; Akarsu E; Erbağci I; Araz M; Okumuş S; Kartal M
Int J Clin Pract; 2007 Jan; 61(1):45-51. PubMed ID: 16889639
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of three different cumulative doses of intravenous methylprednisolone for moderate to severe and active Graves' orbitopathy.
Bartalena L; Krassas GE; Wiersinga W; Marcocci C; Salvi M; Daumerie C; Bournaud C; Stahl M; Sassi L; Veronesi G; Azzolini C; Boboridis KG; Mourits MP; Soeters MR; Baldeschi L; Nardi M; Currò N; Boschi A; Bernard M; von Arx G;
J Clin Endocrinol Metab; 2012 Dec; 97(12):4454-63. PubMed ID: 23038682
[TBL] [Abstract][Full Text] [Related]
10. Therapy of moderate-to-severe Graves' orbitopathy with intravenous methylprednisolone pulses is not associated with loss of bone mineral density.
Rymuza J; Popow M; Żurecka Z; Przedlacki J; Bednarczuk T; Miśkiewicz P
Endocrine; 2019 May; 64(2):308-315. PubMed ID: 30506426
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves' ophthalmopathy: results of a prospective, single-blind, randomized study.
Marcocci C; Bartalena L; Tanda ML; Manetti L; Dell'Unto E; Rocchi R; Barbesino G; Mazzi B; Bartolomei MP; Lepri P; Cartei F; Nardi M; Pinchera A
J Clin Endocrinol Metab; 2001 Aug; 86(8):3562-7. PubMed ID: 11502779
[TBL] [Abstract][Full Text] [Related]
12. Is high dose intravenous methylprednisolone pulse therapy in patients with Graves' orbitopathy safe?
Miśkiewicz P; Kryczka A; Ambroziak U; Rutkowska B; Główczyńska R; Opolski G; Kahaly G; Bednarczuk T
Endokrynol Pol; 2014; 65(5):402-13. PubMed ID: 25301492
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone: a comparison of two dosing regimens.
Sánchez-Ortiga R; Moreno-Pérez O; González Sánchez V; Arias Mendoza N; Mauri Dot M; Alfayate Guerra R; López Macia A; Picó Alfonso A
Endocrinol Nutr; 2009 Mar; 56(3):118-22. PubMed ID: 19627724
[TBL] [Abstract][Full Text] [Related]
14. Intravenous glucocorticoid therapy for Graves' ophthalmopathy and acute liver damage: an epidemiological study.
Sisti E; Coco B; Menconi F; Leo M; Rocchi R; Latrofa F; Profilo MA; Mazzi B; Albano E; Vitti P; Marcocci C; Brunetto M; Marinò M
Eur J Endocrinol; 2015 Mar; 172(3):269-76. PubMed ID: 25661744
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of pulsed intravenous methylprednisolone in early active thyroid eye disease.
Young SM; Lim AYN; Lang SS; Lee KO; Sundar G
Orbit; 2019 Oct; 38(5):362-369. PubMed ID: 30540214
[No Abstract] [Full Text] [Related]
16. High-dose intravenous methylprednisolone therapy in patients with Graves' orbitopathy is associated with the increased activity of factor VIII.
Miśkiewicz P; Milczarek-Banach J; Rutkowska-Hinc B; Kondracka A; Bednarczuk T
J Endocrinol Invest; 2019 Feb; 42(2):217-225. PubMed ID: 29949121
[TBL] [Abstract][Full Text] [Related]
17. Liver Dysfunction Associated with Intravenous Methylprednisolone Pulse Therapy in Patients with Graves' Orbitopathy.
Eguchi H; Tani J; Hirao S; Tsuruta M; Tokubuchi I; Yamada K; Kasaoka M; Teshima Y; Kakuma T; Hiromatsu Y
Int J Endocrinol; 2015; 2015():835979. PubMed ID: 26221141
[TBL] [Abstract][Full Text] [Related]
18. A single-center analysis of visual outcomes and associated factors after intravenous methylprednisolone treatment for dysthyroid optic neuropathy.
Kemchoknatee P; Tangon D; Srisombut T
BMC Ophthalmol; 2023 Jan; 23(1):32. PubMed ID: 36690985
[TBL] [Abstract][Full Text] [Related]
19. [Treatment of Grave's ophthalmopathy with high doses of corticosteroids].
Cirić J; Zarković M; Stojanović M; Pepenezić Z; Randjelović G; Gligorović M; Trbojević B; Drezgić M; Nesović M
Srp Arh Celok Lek; 2000; 128(5-6):179-83. PubMed ID: 11089418
[TBL] [Abstract][Full Text] [Related]
20. A pilot study to monitor Graves' ophthalmopathy with a combination of pattern-reversal and motion-onset visual evoked potentials.
Szanyi J; Kremlacek J; Kubova Z; Langrova J; Kuba M
J Clin Apher; 2012; 27(6):295-301. PubMed ID: 22811284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
